Prescription Required
Formulation: Tablet
(Brand Option)
Select the prescribed dosage
Select the quantity to see the price.
Prescription Required
Formulation: Tablet
(Generic Alternative)
Select the prescribed dosage
Select the quantity to see the price.
* This price includes a dispensing fee, medical review fee, and packing fee.
Shipped and delivered directly to your doorstep
Hepsera (adefovir dipivoxil) is a prescription antiviral medication used to treat chronic hepatitis B virus (HBV) infection.
Chronic hepatitis B is a long-term viral infection that affects the liver. It develops when the hepatitis B virus remains in the body for more than six months.
Over time, the infection can cause ongoing liver inflammation and damage. If left untreated, chronic hepatitis B may increase the risk of liver fibrosis, cirrhosis, liver failure, and liver cancer.
Hepsera contains adefovir dipivoxil, an antiviral medication belonging to a class of drugs called nucleotide analogue reverse transcriptase inhibitors.
It works by interfering with the hepatitis B virus’s ability to reproduce inside liver cells. This helps reduce the amount of virus in the bloodstream and may improve certain signs of liver inflammation.
Hepsera is available as a 10 mg oral tablet. In the United States, it has been approved for certain patients aged 12 years and older with chronic hepatitis B and evidence of active viral replication.
However, Hepsera is no longer a preferred first-line treatment for chronic hepatitis B because newer antiviral medications are generally more effective and have a lower risk of drug resistance.Â
Hepsera is used to treat chronic hepatitis B in patients with an actively reproducing hepatitis B virus.
The hepatitis B virus infects liver cells, where it uses the cells’ internal processes to produce additional viral particles.
As the infection continues, the body’s immune response may cause inflammation and injury to liver tissue.
Persistent liver inflammation can gradually lead to scarring and reduced liver function.
Common symptoms of chronic hepatitis B may include:
However, many people with chronic hepatitis B have no noticeable symptoms, even when liver damage is developing.
Hepsera helps manage chronic hepatitis B by reducing viral replication and lowering the amount of hepatitis B virus in the bloodstream.
Treatment may provide several benefits:
Hepsera does not cure chronic hepatitis B or guarantee that the virus will be completely eliminated from the body.
The medication may reduce viral activity while treatment continues, but hepatitis B can remain in liver cells.
Your healthcare provider may recommend regular blood tests to measure hepatitis B viral load, liver enzyme levels, and kidney function.
The need for treatment depends on the amount of virus in your bloodstream, the degree of liver inflammation, your medical history, and whether liver damage is present.
Hepsera contains adefovir dipivoxil, a nucleotide analogue antiviral medication that interferes with hepatitis B virus replication.
When the hepatitis B virus infects liver cells, it uses an enzyme called HBV DNA polymerase to help produce new copies of its genetic material.
This process allows the virus to multiply and infect additional liver cells.
Adefovir dipivoxil is a prodrug, meaning it is converted into its active form after entering the body.
The active form, adefovir diphosphate, interferes with the viral enzyme needed for hepatitis B DNA replication.
Blocks Hepatitis B Viral Replication
The hepatitis B virus must copy its DNA to produce new viral particles.
Adefovir diphosphate competes with a natural building block used during viral DNA formation.
When the active medication becomes incorporated into the growing viral DNA chain, it prevents the chain from being extended.
This process is called DNA chain termination.
By interrupting viral DNA production, Hepsera reduces the virus’s ability to reproduce.
Reduces Hepatitis B Viral Load
Viral load refers to the amount of hepatitis B virus detected in the bloodstream.
Healthcare providers commonly measure viral load using an HBV DNA blood test.
Higher viral loads may indicate greater viral replication, although the risk of liver damage also depends on other factors.
Hepsera helps reduce viral load by interfering with the production of new hepatitis B virus particles.
Lower viral activity may help reduce ongoing liver inflammation and support better long-term disease management.
However, viral suppression does not mean that hepatitis B has been completely eliminated.
Helps Reduce Liver Inflammation
Chronic hepatitis B can cause the immune system to react continuously to infected liver cells.
This ongoing response may damage liver tissue and cause elevated liver enzymes.
ALT and aspartate aminotransferase (AST) are enzymes commonly measured through blood tests to assess liver inflammation or injury.
By reducing hepatitis B replication, Hepsera may help lower inflammation associated with active viral infection.
Some patients experience improvements in liver enzyme levels and other markers of liver health during treatment.
However, the medication does not directly repair established liver scarring or guarantee that liver damage will reverse.
Helps Limit Further Liver Damage
Persistent hepatitis B infection may gradually damage healthy liver tissue.
Repeated inflammation can lead to fibrosis, which occurs when scar tissue forms inside the liver.
Advanced fibrosis can progress to cirrhosis, a condition in which extensive scarring interferes with normal liver function.
Effective antiviral treatment may reduce ongoing viral activity and the risk of further liver complications.
However, people with chronic hepatitis B may still require long-term monitoring for cirrhosis and liver cancer, even when their viral load becomes very low.
Hepsera begins interfering with hepatitis B viral replication after the medication is absorbed and converted into its active form.
However, meaningful reductions in viral load generally develop over weeks to months rather than immediately.
Some patients may show improvements in HBV DNA levels and liver enzyme results during the first several months of treatment.
Your healthcare provider will use blood tests to assess whether the medication is effectively controlling the infection.
These tests may include HBV DNA measurements, liver function tests, and kidney function tests.
The duration of treatment depends on your liver condition, treatment response, viral resistance, and other medical factors.
Do not stop taking Hepsera without consulting your healthcare provider.
Stopping hepatitis B antiviral therapy may cause the virus to become more active again, potentially leading to a serious worsening of hepatitis.
Hepsera is generally taken once daily, with or without food, when prescribed for patients with adequate kidney function.
Because adefovir is removed from the body through the kidneys, people with reduced kidney function may require changes to their dosing schedule.
Hepsera can cause kidney problems, particularly during prolonged treatment or in patients with existing kidney impairment.
Your healthcare provider should monitor your kidney function during treatment.
Hepsera is not recommended as a treatment for HIV infection. Patients should be tested for HIV before starting Hepsera because using adefovir without appropriate HIV treatment may contribute to antiviral resistance.
Tell your healthcare provider about all medications you take, especially those that may affect kidney function.
Hepsera helps control chronic hepatitis B by blocking viral DNA replication, reducing viral load, and improving certain markers of liver inflammation. However, it does not cure the infection, and ongoing medical monitoring remains necessary.
Hepsera remains an established antiviral medication for chronic hepatitis B, but it is not generally recommended as a first-line treatment.
Current treatment guidelines favor antiviral medications such as entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide.
These medications generally provide stronger viral suppression and have a lower likelihood of developing antiviral resistance.
Hepsera may still be considered in selected circumstances when more suitable treatments are unavailable or inappropriate, depending on local prescribing guidance.
Your healthcare provider will determine the most appropriate treatment based on your liver condition, kidney function, previous antiviral treatments, and medical history.Â
Hepsera is a prescription antiviral medication used to treat chronic hepatitis B virus (HBV) infection.
Hepsera belongs to a class of medications called nucleotide analogue antivirals. It works by blocking the replication of the hepatitis B virus, helping reduce viral activity and protect the liver from further damage.
Hepsera is available as a 10 mg oral tablet and is generally taken once daily, with or without food.
Your healthcare provider will determine the appropriate dosage based on your kidney function, medical history, and response to treatment.
Taking Hepsera regularly is important because missed doses or stopping treatment without medical advice may allow the hepatitis B virus to become more active.
Follow these instructions to take Hepsera correctly and safely:
Hepsera helps control hepatitis B but does not cure the infection. Ongoing treatment and regular monitoring may be necessary.
The recommended dosage depends on your age, kidney function, and treatment needs.
For adults with adequate kidney function, Hepsera is generally prescribed as one 10 mg tablet taken once daily.
| Dosage information | General instructions |
| Medication | Hepsera (adefovir dipivoxil) |
| Dosage form | Oral tablet |
| Tablet strength | 10 mg |
| Usual adult dosage | 10 mg once daily |
| Administration | By mouth |
| Food requirements | With or without food |
| Kidney impairment | Dosing interval may need adjustment |
| Treatment duration | As directed by your healthcare provider |
People with reduced kidney function may require longer intervals between doses because adefovir is eliminated primarily through the kidneys.
Your healthcare provider may recommend kidney function tests before treatment begins and periodically during treatment.
Do not adjust your dosage schedule without medical advice.
Take Hepsera Consistently
Hepsera works by interfering with the hepatitis B virus’s ability to produce new copies of itself.
Taking the medication consistently helps maintain antiviral treatment and supports viral suppression.
Because chronic hepatitis B may not cause noticeable symptoms, you may feel healthy even when the infection remains active.
Do not stop taking Hepsera simply because you feel better or your blood test results have improved.
Your healthcare provider will determine how long treatment should continue.
Do Not Stop Treatment Suddenly
Stopping Hepsera may cause the hepatitis B virus to become more active.
This can lead to a serious worsening of hepatitis, sometimes called a hepatitis flare.
A flare may cause increased liver inflammation and, in severe cases, significant liver injury.
Possible symptoms include unusual fatigue, nausea, abdominal pain, dark urine, and yellowing of the skin or eyes.
Your healthcare provider may recommend close monitoring of your liver function if treatment needs to be stopped.
Do not discontinue Hepsera without consulting your healthcare provider, even if your symptoms have improved.
HIV Testing Before and During Treatment
Tell your healthcare provider if you have HIV or believe you may have been exposed to the virus.
Some people can have both chronic hepatitis B and HIV because the viruses share certain routes of transmission.
Hepsera should not be used alone to treat hepatitis B in people who also have untreated HIV infection.
Adefovir does not provide an appropriate complete treatment for HIV, and using it without an effective HIV treatment plan may contribute to antiviral resistance.
Your healthcare provider should recommend HIV testing before starting Hepsera.
Additional testing may be appropriate during treatment if you have ongoing HIV exposure risks or new symptoms suggesting infection.
If you have both hepatitis B and HIV, your healthcare provider will recommend an antiviral treatment plan that appropriately manages both infections.
Monitor Your Kidney Function
Hepsera may cause kidney-related side effects, particularly with prolonged treatment or in people with existing kidney problems.
The kidneys remove adefovir from the bloodstream.
If kidney function is reduced, the medication may accumulate in the body.
Your healthcare provider may recommend blood tests to monitor kidney function before and during treatment.
These may include serum creatinine measurements and other tests used to assess how effectively your kidneys are working.
Tell your healthcare provider if you have kidney disease or take medications that may affect kidney function.
Report unusual weakness, changes in urination, or other new symptoms during treatment.
Attend Regular Hepatitis B Monitoring
Your healthcare provider may recommend regular blood tests to assess your response to Hepsera.
These tests may include hepatitis B viral load measurements, liver enzyme levels, and kidney function tests.
Viral load testing measures the amount of hepatitis B virus in your bloodstream.
Liver function tests help assess inflammation or possible liver injury.
If your viral load does not decrease as expected or begins increasing again, your healthcare provider may investigate whether the virus has developed resistance to adefovir.
Treatment resistance occurs when changes in the virus reduce its response to antiviral medication.
Your healthcare provider may recommend changing to another antiviral treatment if Hepsera is no longer controlling the infection effectively.
If you forget to take Hepsera at your usual time, take the missed dose as soon as you remember on the same day.
If you do not remember until the following day, skip the missed dose and continue with your regular schedule.
Do not take two doses at once to make up for a missed dose.
Taking more Hepsera than prescribed may increase the risk of side effects, including kidney problems.
If you frequently miss doses, consider using a medication reminder or taking Hepsera at the same time each day.
If you are unsure how to manage a missed dose, particularly if you have kidney impairment and follow an adjusted dosing schedule, contact your healthcare provider or pharmacist.Â
The length of treatment with Hepsera depends on your hepatitis B viral load, liver function, medical history, and response to antiviral therapy.
Some people may require treatment for an extended period to keep the hepatitis B virus under control.
Hepsera does not eliminate the virus completely, so stopping treatment may allow viral replication to increase again.
Your healthcare provider will monitor your HBV DNA levels and liver function to determine whether treatment remains appropriate.
Because adefovir resistance can develop during prolonged treatment, your healthcare provider may recommend changing to another antiviral medication if your viral load stops decreasing or begins increasing.
Do not discontinue Hepsera without medical advice. If treatment is stopped, your healthcare provider should monitor your liver function closely for several months because serious hepatitis flare-ups may occur.Â
Contact your healthcare provider if you develop new symptoms, notice a worsening of your hepatitis B symptoms, or experience unusual side effects during treatment.
Symptoms such as increasing fatigue, persistent nausea, dark urine, abdominal swelling, or yellowing of the skin or eyes may indicate worsening liver problems.
You should also report changes in urination, unusual muscle weakness, or significant fatigue, as these may be associated with kidney problems or other medication-related complications.
Seek urgent medical attention if you develop severe abdominal pain, confusion, significant jaundice, or other signs of serious liver complications.
Taking Hepsera consistently is important for managing chronic hepatitis B. Follow your prescribed dosage, attend regular blood tests, and report any new or worsening symptoms to your healthcare provider.
Hepsera (Adefovir) is available in the following forms and strength:
Before taking Hepsera, tell your healthcare provider about any medical conditions, allergies, or medications you are taking.
Hepsera is a prescription antiviral medication used to treat chronic hepatitis B virus (HBV) infection. It works by slowing the replication of the hepatitis B virus, helping reduce viral activity and liver inflammation.
Although Hepsera can help control chronic hepatitis B, it may cause serious side effects, particularly involving the liver and kidneys.
Some people may also develop changes in blood phosphate levels, bone health, or acid balance.
Your healthcare provider may recommend regular blood tests to monitor your liver function, kidney function, and response to antiviral treatment.
Stopping Hepsera may cause a serious worsening of hepatitis B, sometimes called a hepatitis flare.
Hepsera helps control the hepatitis B virus by reducing its ability to reproduce. However, the medication does not completely eliminate the virus from the body.
When treatment stops, the virus may begin multiplying more rapidly.
This increase in viral activity can trigger inflammation and damage to the liver.
Possible symptoms of worsening hepatitis B include:
In severe cases, a hepatitis flare may lead to liver failure, particularly in people who already have significant liver damage.
Do not stop taking Hepsera without consulting your healthcare provider.
If your treatment needs to be discontinued, your healthcare provider should monitor your liver function closely for several months.
Contact your healthcare provider promptly if you develop new or worsening symptoms during treatment or after stopping Hepsera.
Hepsera may cause kidney problems, particularly in people with existing kidney disease or those taking medications that can damage the kidneys.
Adefovir is removed from the body primarily through the kidneys.
When kidney function becomes impaired, the medication may accumulate in the bloodstream, increasing the risk of unwanted effects.
Hepsera has been associated with kidney toxicity, including reduced kidney function and, in severe cases, kidney failure.
Possible symptoms of kidney problems include:
Kidney damage may develop without noticeable symptoms during its early stages.
For this reason, your healthcare provider may recommend blood tests to measure serum creatinine and assess how well your kidneys are working.
People with reduced kidney function may require a longer interval between Hepsera doses.
Tell your healthcare provider if you have chronic kidney disease, a history of kidney problems, or take medications that may affect kidney function.
Do not increase your dosage or change your dosing schedule without medical advice.
Hepsera may cause Fanconi syndrome, a rare but serious kidney disorder affecting the proximal tubules.
The proximal tubules are small structures inside the kidneys that help return important substances from filtered urine to the bloodstream.
These substances include glucose, phosphate, bicarbonate, and certain amino acids.
In Fanconi syndrome, the kidneys lose their ability to reabsorb some of these substances properly.
As a result, important minerals and nutrients may be lost through the urine.
Possible symptoms include:
Fanconi syndrome may also cause low phosphate levels and changes in the body’s acid balance.
The risk may be higher with prolonged exposure to adefovir or in people who already have reduced kidney function.
Your healthcare provider may recommend kidney function tests and, when appropriate, blood phosphate measurements.
Contact your healthcare provider if you develop unexplained muscle weakness, persistent bone pain, or changes in urination.
Hepsera may rarely cause lactic acidosis, a serious condition in which too much lactic acid builds up in the bloodstream.
Lactic acid is naturally produced when the body breaks down glucose to generate energy.
Normally, the body maintains a balance between lactic acid production and removal.
Certain antiviral medications can interfere with how cells produce energy, increasing the risk of lactic acid accumulation.
Lactic acidosis can affect normal organ function and may become life-threatening without prompt treatment.
Possible symptoms include:
Lactic acidosis is uncommon, but it requires immediate medical attention.
Severe liver disease may increase the risk of complications involving acid balance and medication processing.
Seek emergency medical attention if you develop severe weakness, unusual breathing difficulties, persistent vomiting, or other symptoms suggesting lactic acidosis.
Your healthcare provider will determine whether Hepsera should be stopped and whether additional treatment is necessary.
Hepsera may contribute to bone problems in some people, particularly when treatment causes kidney damage or low phosphate levels.
Phosphate is an essential mineral that helps maintain strong bones and teeth. It also supports normal muscle function and energy production.
When Hepsera affects the kidneys, excessive phosphate may be lost through the urine. Over time, this can interfere with normal bone mineralization.
Some people may develop a condition called osteomalacia, which causes bones to become soft and weak.
Possible symptoms include:
Bone complications associated with Hepsera are often linked to kidney problems that cause phosphate loss rather than a direct effect on bone density.
Tell your healthcare provider if you develop persistent bone pain, unexplained muscle weakness, or difficulty walking.
Your healthcare provider may recommend blood tests to check phosphate levels and kidney function. Additional bone examinations may be needed if symptoms suggest osteomalacia.Â
Hepsera may cause hypophosphatemia, a condition in which phosphate levels in the bloodstream become too low.
Phosphate is important for healthy bones, muscle movement, nerve function, and the production of energy inside cells.
The kidneys normally help maintain phosphate balance by returning the amount the body needs to the bloodstream.
However, Hepsera can sometimes damage the kidney tubules, causing excessive phosphate to be lost through the urine.
When phosphate levels remain low, bones and muscles may become weaker.
Possible symptoms include:
Severe phosphate deficiency may cause significant muscle problems and other complications.
Tell your healthcare provider if you have previously experienced low phosphate levels, kidney problems, or unexplained bone pain.
Your healthcare provider may recommend phosphate testing, especially if you are receiving long-term treatment or have signs of kidney injury.
Do not begin phosphate supplements without medical advice.
Do not take Hepsera if you are allergic to adefovir dipivoxil or any other ingredient in the medication.
An allergic reaction occurs when the immune system reacts to a substance it identifies as harmful.
Although allergic reactions to Hepsera are uncommon, they may cause symptoms ranging from mild skin irritation to severe breathing difficulties.
Possible symptoms include:
Tell your healthcare provider about any previous allergic reactions to antiviral medications.
Stop taking Hepsera and contact your healthcare provider if you develop a suspected allergic reaction.
Seek emergency medical attention immediately if you experience difficulty breathing or swelling of your tongue or throat.
Hepsera may interact with medications that affect kidney function or are removed from the body through the kidneys.
Because adefovir is primarily eliminated by the kidneys, combining it with certain medications may increase the risk of kidney-related side effects.
Medications that may require additional precautions include:
Hepsera should not be taken together with tenofovir-containing medications, including products containing tenofovir disoproxil fumarate or tenofovir alafenamide, unless a specialist has specifically reassessed the treatment plan. The product information advises against this combination.
Before starting Hepsera, tell your healthcare provider about all prescription medications, over-the-counter drugs, vitamins, and herbal supplements you use.
Your healthcare provider may recommend kidney function monitoring or an alternative medication to reduce the risk of interactions.
Do not start, stop, or change another medication without medical advice.Â
Tell your healthcare provider if you have HIV or believe you may have been exposed to the virus.
Some people may have both chronic hepatitis B and HIV because these infections share certain routes of transmission.
Hepsera is not an appropriate standalone treatment for HIV infection.
Using adefovir in someone who has unrecognized or untreated HIV may contribute to the development of HIV drug resistance.
Drug resistance occurs when changes in a virus reduce its response to medications.
Your healthcare provider should offer HIV testing before starting Hepsera.
If you have both hepatitis B and HIV, you will need a treatment plan that appropriately manages both infections.
Do not use Hepsera as the only antiviral medication if you have HIV coinfection.Â
Tell your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding before taking Hepsera.
There is limited information about the safety of adefovir dipivoxil during human pregnancy.
Although animal studies have not identified certain developmental problems at studied doses, these findings do not establish that Hepsera is safe for pregnant women.
Your healthcare provider will consider the potential benefits of antiviral treatment and any possible risks to the developing baby.
Chronic hepatitis B may also require special monitoring during pregnancy, including assessment of the mother’s viral load and planning to reduce the risk of transmission to the baby.
Other hepatitis B medications with more established pregnancy safety information may be preferred.
It is not known whether adefovir passes into human breast milk in clinically important amounts.
If you are breastfeeding, your healthcare provider will help determine whether Hepsera is appropriate or whether another treatment should be considered.
Do not start or stop hepatitis B treatment during pregnancy or breastfeeding without medical advice.
Hepsera is not recommended for children younger than 12 years of age.
The safety and effectiveness of adefovir dipivoxil have not been established for this age group.
Under U.S. prescribing information, Hepsera has been approved for certain adolescents aged 12 years and older with chronic hepatitis B and evidence of active viral replication.
However, treatment choices for children and adolescents depend on several factors, including age, body weight, liver function, viral load, and overall health.
Children with chronic hepatitis B should be evaluated by a healthcare provider experienced in treating pediatric liver disease.
Do not give Hepsera to a child without specific medical instructions.Â
Regular blood tests are important during Hepsera treatment because certain side effects may develop before noticeable symptoms appear.
Your healthcare provider may monitor:
Your healthcare provider may also monitor for antiviral resistance if your hepatitis B viral load stops decreasing or begins increasing again.
Attend scheduled medical appointments, even if you feel well.
Chronic hepatitis B and medication-related kidney problems may not always cause symptoms during their early stages.
Contact your healthcare provider promptly if you experience unusual fatigue, persistent nausea, worsening abdominal discomfort, changes in urination, muscle weakness, or unexplained bone pain.
You should also report any signs of worsening hepatitis B, including dark urine, jaundice, or increasing abdominal swelling.
Seek urgent medical attention if you develop severe weakness, persistent vomiting, significant changes in urination, or worsening jaundice.
Seek emergency medical attention if you experience difficulty breathing, confusion, severe abdominal pain, or symptoms suggesting lactic acidosis or liver failure.
Hepsera helps control chronic hepatitis B, but careful monitoring is essential to reduce treatment-related risks. Taking the medication as prescribed, attending regular liver and kidney tests, and reporting new symptoms can help identify complications early.
The length of treatment with Hepsera depends on your hepatitis B viral load, liver function, medical history, and response to treatment. Hepsera is a prescription antiviral medication used to treat chronic hepatitis B virus (HBV) infection. It works by slowing the virus’s ability to reproduce, helping reduce viral activity and liver inflammation. Chronic hepatitis B is a long-term infection, so some people may need antiviral treatment for several years. However, the ideal treatment duration varies, and there is no single treatment period that is appropriate for everyone. Your healthcare provider may recommend regular blood tests to monitor your HBV DNA levels, liver enzymes, and kidney function. These tests help determine whether the medication is controlling the infection and whether treatment should continue. Although some people have taken Hepsera for several years, long-term use may increase the risk of kidney problems and antiviral resistance. For this reason, your healthcare provider will regularly review whether Hepsera remains the most appropriate treatment. Do not stop taking Hepsera without consulting your healthcare provider. Stopping antiviral treatment may cause the hepatitis B virus to become active again, potentially leading to a serious worsening of liver inflammation. If treatment needs to be stopped, your healthcare provider will monitor your liver function closely for several months to detect possible complications.
Hepsera may be considered during pregnancy only when a healthcare provider determines that the potential benefits outweigh the possible risks. There is limited information about the safety of adefovir dipivoxil during human pregnancy. Although animal studies have provided some information about its effects, there is not enough evidence to confirm that Hepsera is safe for pregnant women. Chronic hepatitis B requires careful management during pregnancy because the infection can affect liver health and may be transmitted from mother to baby during childbirth. Your healthcare provider may recommend blood tests to measure your hepatitis B viral load and assess your liver function. Depending on your condition, another antiviral medication with more established pregnancy safety information, such as tenofovir, may be preferred. Your healthcare provider will consider the severity of your hepatitis B infection, the need for continued antiviral treatment, and any potential risks to your baby. If you become pregnant while taking Hepsera, contact your healthcare provider promptly to review your treatment plan. Do not stop taking Hepsera suddenly without medical advice. Stopping hepatitis B treatment may cause a serious increase in viral activity and liver inflammation. Your healthcare provider will help determine the safest and most appropriate treatment during pregnancy.
Yes, Hepsera may interact with certain medications, particularly those that affect kidney function. Hepsera contains adefovir dipivoxil, an antiviral medication that is removed from the body primarily through the kidneys. Taking Hepsera with other medications that affect the kidneys may increase the risk of kidney damage or change how the medication is eliminated from your body. Certain medications require additional precautions when used with Hepsera. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, may affect kidney function, especially when taken at high doses or for extended periods. Aminoglycoside antibiotics, such as gentamicin, may also increase the risk of kidney damage. Immunosuppressant medications, including cyclosporine and tacrolimus, can affect kidney function and may require additional monitoring. Combining Hepsera with other antiviral medications that affect the kidneys may increase the risk of side effects. In particular, Hepsera should not be taken with tenofovir-containing medications because of overlapping antiviral activity and potential safety concerns. Some vitamins, herbal supplements, and natural health products may also affect kidney function or interfere with your treatment. Before starting Hepsera, tell your healthcare provider or pharmacist about all prescription medications, over-the-counter drugs, supplements, and herbal products you use. Providing a complete medication list can help identify possible interactions and reduce the risk of complications. Your healthcare provider may recommend regular kidney function tests, adjust your medication schedule, or prescribe an alternative treatment if a significant interaction is identified. These precautions can help protect your kidneys while ensuring that your hepatitis B treatment remains effective. Do not start, stop, or change any medication or supplement without consulting your healthcare provider. Regular medication reviews and kidney function monitoring can help reduce the risk of drug interactions and kidney-related complications during Hepsera treatment.
Hepsera may be prescribed to certain children and adolescents aged 12 years and older with chronic hepatitis B, depending on the approved indications in their country. Under U.S. prescribing information, Hepsera is approved for patients aged 12 years and older who have chronic hepatitis B with evidence of active viral replication and liver inflammation or disease. However, Hepsera is not recommended for children younger than 12 years because its safety and effectiveness have not been established in this age group. Children with chronic hepatitis B require careful evaluation because their treatment needs may differ from those of adults. Your healthcare provider will consider the child’s age, liver function, hepatitis B viral load, kidney function, and overall health before recommending antiviral treatment. Children and adolescents receiving Hepsera may require regular blood tests to monitor their response to treatment and identify possible side effects. Hepsera is also not generally a preferred first-line treatment for pediatric hepatitis B because newer antiviral medications may offer better viral suppression and a lower risk of resistance. A healthcare provider experienced in treating children with liver disease should determine the most appropriate medication and treatment schedule. Do not give Hepsera to a child without a prescription or change the prescribed dosage without medical advice.
| Generic name: | Adefovir, Adefovir Dipivoxil |
|---|---|
| Formulation: | Tablet |
| Strength(s): | 10mg |
| Quantities Available: | 30, 90 |
Our online Canadian Pharmacy is known for high standards of quality, safety, and efficiency when it comes to medications.
Our pharmacy offers lower prices on prescription drugs compared to traditional pharmacies.
When ordering Hepsera (adefovir) from a Canadian pharmacy, you can typically purchase up to a 90-day supply at one time, which is common for prescription medications to ensure adequate management of chronic conditions without frequent refills.
Here’s what you need to know:
Dosage and Quantity: Hepsera is commonly prescribed in a dosage of 10 mg, taken once daily. For a 90-day supply, this means you would order 90 tablets (90 days x 1 tablet per day).
Yes, we sell adefovir on our website. You can enjoy low prices when you order through us. To purchase adefovir, you will need a valid prescription from your healthcare provider. We require this prescription to dispense the medication safely and appropriately. You can submit your prescription by mailing it to us, faxing it, or uploading it through your online account.
Yes, we ship Hepsera (adefovir) to both the United States and Puerto Rico.
Watch how Online Pharmacies Canada is helping customers save money on their medications.
Online Pharmacies Canada has provided information from third parties intended to increase awareness and does not contain all the information about Hepsera (Adefovir). Talk to your doctor or other qualified medical practitioners for medical attention or advice, or if you have any concerns about Hepsera (Adefovir).
REVIEWS